Compare Dyne Therapeutics Inc. Common Stock (DYN) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs HubSpot Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while HubSpot Inc trades at $223.77 (market cap $11.03B). The key difference: HubSpot Inc is far larger — about 3.9× Dyne Therapeutics Inc. Common Stock's market cap, and HubSpot Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and HubSpot Inc for 78 Days on average.
| DYN | HUBS | |
|---|---|---|
Market Cap | $2.86B | $11.03B |
Volume | 3,341,579 | 784,639 |
Sector | Health | Technology |
52-Week High | $26.78 | $494.58 |
52-Week Low | $14.60 | $170.39 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $2.18B | $9.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
HubSpot (HUBS) trades at $226.23, up 1.28% today, with a neutral technical signal and strong fundamental growth. The stock has beaten earnings estimates for the last three quarters, with revenue growing from $1.7B in 2022 to $3.1B in 2025. Recent news highlights an AI-focused strategy and partnership with OpenAI, aiming to boost margins and customer outcomes.
The outlook is positive with 55% analyst buy ratings and a $244.09 consensus price target, suggesting 8% upside. Key risks include high valuation multiples and competitive pressures in the SaaS space. Cash flow growth and institutional accumulation support the bullish case, but investors should monitor execution of AI initiatives and margin targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
